株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

ナチュラルキラー(NK)細胞療法の世界市場:治療法、用途、エンドユーザー別 - 機会分析および業界予測(2018年~2026年)

Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026

発行 Allied Market Research 商品コード 908559
出版日 ページ情報 英文 217 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.87円で換算しております。
Back to Top
ナチュラルキラー(NK)細胞療法の世界市場:治療法、用途、エンドユーザー別 - 機会分析および業界予測(2018年~2026年) Natural Killer Cells Therapeutics Market by Therapeutics, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2026
出版日: 2019年07月01日 ページ情報: 英文 217 Pages
概要

当レポートは世界のナチュラルキラー(NK)細胞療法について調査し、市場機会、成長および阻害要因、治療法・用途・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
  • 利害関係者の主な利点
  • 主要市場セグメント
  • 調査方法
    • 二次調査
    • 一次調査
    • アナリストのツールおよびモデル

第2章 エグゼクティブサマリー

  • CXOの見識

第3章 市場の概観

  • 市場の定義および範囲
  • 主な調査結果
    • 主な投資銘柄
    • 成功戦略
  • ポーターのファイブフォース分析
  • 主要企業の位置づけ
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 政府規制シナリオ
    • 米国
    • 欧州
    • 日本
    • タイ
    • シンガポール
    • マレーシア
    • メキシコ
    • オーストラリア

第4章 世界市場:治療薬別

  • 概要
    • 市場および予測
  • NK細胞療法
    • 主要な市場動向および機会
    • 市場規模および予測:地域別
    • 市場分析:国別
  • NK細胞向け抗体

第5章 世界市場:用途別

  • 概要
    • 市場規模および予測:地域別
    • 市場規模および予測:地域別
    • 市場分析:国別
  • 消化器疾患
  • 免疫増殖性疾患
  • その他

第6章 世界市場:エンドユーザー別

  • 概要
    • 市場および予測
  • 研究センターおよび研究所
    • 市場および予測:地域別
    • 市場分析:国別
  • 病院および診療所
  • その他

第7章 世界市場:地域別

  • 概要
    • 市場規模および予測
  • 北米
    • 主要な市場動向および機会
    • 治療法別
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第8章 企業プロファイル

  • AFFIMED N.V.
  • CELGENE CORPORATION
  • FATE THERAPEUTICS INC.
  • FORTRESS BIOTECH
  • GLYCOSTEM THERAPEUTICS BV
  • INNATE PHARMA SA
  • NANTKWEST INC
  • NKARTA THERAPEUTICS, INC.
  • NKT THERAPEUTICS INC.
  • ZIOPHARM ONCOLOGY INC.
図表

List of Tables

  • TABLE 01. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2026 ($MILLION)
  • TABLE 02. GLOBAL NATURAL KILLER CELL THERAPIES MARKET, BY REGION 2018-2026 ($MILLION)
  • TABLE 03. GLOBAL NK CELL-DIRECTED ANTIBODIES MARKET, BY REGION 2018-2026 ($MILLION)
  • TABLE 04. NATURAL KILLER CELL THERAPEUTICS MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 05. CANCER NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 06. NATURAL KILLER CELL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION 2018-2026, ($MILLION)
  • TABLE 07. NATURAL KILLER CELL THERAPEUTICS MARKET FOR IMMUNOPROLIFERATIVE DISORDERS, BY REGION 2018-2026, ($MILLION)
  • TABLE 08. NATURAL KILLER CELL THERAPEUTICS MARKET FOR OTHERS, BY REGION 2018-2026, ($MILLION)
  • TABLE 09. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER, 2018-2026 ($MILLION)
  • TABLE 10. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY RESEARCH CENTERS AND INSTITUTES, 2018-2026 ($MILLION)
  • TABLE 11. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018-2026 ($MILLION)
  • TABLE 12. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018-2026 ($MILLION)
  • TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET BY REGION, 2018-2026, ($MILLION)
  • TABLE 14. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2026 ($MILLION)
  • TABLE 15. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 16. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 17. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 18. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 19. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 20. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 21. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 22. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 23. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 24. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 25. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 26. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 27. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 28. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 29. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 30. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 31. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 32. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 33. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 34. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 35. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 36. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 37. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 38. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 39. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 40. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 41. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 42. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 43. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 44. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 45. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 46. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 47. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 48. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 49. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 50. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 51. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 52. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 53. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 54. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 55. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 56. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 57. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 58. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 59. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 60. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 61. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 62. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 63. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 64. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 65. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 68. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 69. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 70. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 71. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 72. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 73. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 74. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 75. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 76. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 77. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 78. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 79. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 80. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 81. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
  • TABLE 82. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 83. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
  • TABLE 84. AFFIMED NV: COMPANY SNAPSHOT
  • TABLE 85. AFFIMED NV: OPERATING SEGMENTS
  • TABLE 86. AFFIMED NV: PRODUCT PORTFOLIO
  • TABLE 87. CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 88. CELGENE CORPORATION: PRODUCT SEGMENTS
  • TABLE 89. CELGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 90. FATE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 91. FATE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 92. FATE THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 93. FORTRESS BIOTECH: COMPANY SNAPSHOT
  • TABLE 94. FORTRESS BIOTECH: PRODUCT PORTFOLIO
  • TABLE 95. GLYCOSTEM THERAPEUTICS BV: COMPANY SNAPSHOT
  • TABLE 96. GLYCOSTEM THERAPEUTICS BV: OPERATING SEGMENTS
  • TABLE 97. GLYCOSTEM THERAPEUTICS BV: PRODUCT PORTFOLIO
  • TABLE 98. INNATE PHARMA SA: COMPANY SNAPSHOT
  • TABLE 99. INNATE PHARMA SA: OPERATING SEGMENTS
  • TABLE 100. INNATE PHARMA SA: PRODUCT PORTFOLIO
  • TABLE 101. NANTKWEST INC.: COMPANY SNAPSHOT
  • TABLE 102. NANTKWEST INC.: OPERATING SEGMENTS
  • TABLE 103. NANTKWEST INC.: PRODUCT PORTFOLIO
  • TABLE 104. NKARTA THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 105. NKARTA THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 106. NKARTA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 107. NKT THERAPEUTICS INC: COMPANY SNAPSHOT
  • TABLE 108. NKT THERAPEUTICS INC.: OPERATING SEGMENTS
  • TABLE 109. NKT THERAPEUTICS INC.: PRODUCT PORTFOLIO
  • TABLE 110. ZIOPHARM ONCOLOGY INC: COMPANY SNAPSHOT
  • TABLE 111. ZIOPHARM ONCOLOGY INC: OPERATING SEGMENTS
  • TABLE 112. ZIOPHARM ONCOLOGY INC.: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
  • FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
  • FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
  • FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 08. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 09. MODERATE THREAT OF SUBSTITUTION
  • FIGURE 10. MODERATE COMPETITIVE RIVALRY
  • FIGURE 11. TOP PLAYER POSITIONING
  • FIGURE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
  • FIGURE 13. NK CELL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 14. NK CELL-DIRECTED ANTIBODIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 15. CANCER MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 16. GASTROINTESTINAL DISEASES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 17. IMMUNOPROLIFERATIVE DISORDERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 18. OTHER MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 19. RESEARCH CENTERS AND INSTITUTES THERAPEUTICS MARKET, BY REGION, 2017-2025 ($MILLION)
  • FIGURE 20. HOSPITALS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 21. OTHERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • FIGURE 22. AFFIMED NV: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23. AFFIMED NV: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 24. CELGENE CORPORATION: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 25. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2018(%)
  • FIGURE 26. CELGENE CORPORATION: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 27. FATE THERAPEUTICS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 28. FORTRESS BIOTECH: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 29. FORTRESS BIOTECH: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 30. INNATE PHARMA SA: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 31. NANTKWEST INC.: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 32. ZIOPHARM ONCOLOGY INC: NET SALES, 2016-2018 ($MILLION)
目次
Product Code: LI_182132

Natural killer (NK) cell is a component of innate immunity system that targets cancer cells, and can be used as a therapeutic agent. NK cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood.

The global natural killer cell therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.

The growth of the global natural killer cell therapeutics market is driven by rise in use of NK cells to treat cancer, infections, and liver diseases. Moreover, NK cells play vital role in tumor immune-surveillance, which has significantly boosted their adoption across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cell therapeutics market growth. However, lack of specificity and poor in-vivo survival of the cells limit the growth of the market. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. Conversely, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to offer lucrative opportunities for the market.

The global natural killer cell therapeutics market is segmented based on therapeutics, application, end user, and region. Depending on therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. By application, it is categorized into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. On the basis of end user, it is segregated into hospitals, research centers & institutes, and others. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The global natural killer cell therapeutics market size and estimations are based on a comprehensive analysis of key developments.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Therapeutics

  • NK Cell Therapies
  • NK Cell Directed Antibodies

By Application

  • Cancer
  • Gastrointestinal Diseases
  • Immunoproliferative Disorders
  • Others

By End User

  • Research Centers & Institutes
  • Hospitals
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

The key players profiled in this report are as follows:

  • Affimed N.V.
  • Celgene Corporation
  • Fate Therapeutics
  • Fortress Biotech
  • Glycostem Therapeutics BV
  • Innate Pharma S.A.
  • Nantkwest Inc.
  • Nkarta Therapeutics, Inc.
  • NKT Therapeutics Inc.
  • Ziopharm Oncology Inc.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Porter's five forces analysis
  • 3.4. Top player positioning
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Rise in incidence of cancer across the globe
      • 3.5.1.2. Increase in government expenditure on healthcare
      • 3.5.1.3. Surge in awareness regarding immunotherapy
    • 3.5.2. Restraints
      • 3.5.2.1. High cost of cancer immunotherapy treatment
      • 3.5.2.2. Stringent government regulations toward approval of immunotherapy
    • 3.5.3. Opportunity
      • 3.5.3.1. Surge in R&D activities toward the development of immunotherapy
  • 3.6. Government regulatory scenerio
    • 3.6.1. U.S.
    • 3.6.2. Europe
    • 3.6.3. Japan
    • 3.6.4. Thailand
    • 3.6.5. Singapore
    • 3.6.6. Malaysia
    • 3.6.7. Mexico
    • 3.6.8. Australia

CHAPTER 4: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS

  • 4.1. Overview
    • 4.1.1. Market and forecast
  • 4.2. Natural killer cell therapies
    • 4.2.1. Key market trends and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
      • 4.2.3.1. CNDO-109
      • 4.2.3.2. oNKord
      • 4.2.3.3. Natural Killer Cells
      • 4.2.3.4. Others
  • 4.3. NK cell-directed antibodies
    • 4.3.1. Key market trends and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
      • 4.3.3.1. MOGAMULIZUMAB
      • 4.3.3.2. Lirilumab
      • 4.3.3.3. AFM13
      • 4.3.3.4. NKTT 120
      • 4.3.3.5. Others

CHAPTER 5: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast, by region
  • 5.2. Cancer
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by country
  • 5.3. Gastrointestinal diseases
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by country
  • 5.4. Immunoproliferative disorders
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market analysis, by country
  • 5.5. Others
    • 5.5.1. Market size and forecast
    • 5.5.2. Market analysis, by country

CHAPTER 6: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market and forecast
  • 6.2. Research centers and institutes
    • 6.2.1. Market and forecast, by region
    • 6.2.2. Market analysis, by country
  • 6.3. Hospitals and clinics
    • 6.3.1. Market and forecast, by region
    • 6.3.2. Market analysis, by country
  • 6.4. Others
    • 6.4.1. Market and forecast, by region
    • 6.4.2. Market analysis, by country

CHAPTER 7: NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends and opportunities
    • 7.2.2. Market size and forecast, by therapeutics
    • 7.2.3. Market size and forecast, by application
    • 7.2.4. Market size and forecast, by application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S. market size and forecast, by therapeutics
      • 7.2.5.2. U.S. market size and forecast, by application
      • 7.2.5.3. U.S. market size and forecast, by end user
      • 7.2.5.4. Canada market size and forecast, by therapeutics
      • 7.2.5.5. Canada market size and forecast, by application
      • 7.2.5.6. Canada market size and forecast, by end user
      • 7.2.5.7. Mexico market size and forecast, by therapeutics
      • 7.2.5.8. Mexico market size and forecast, by application
      • 7.2.5.9. Mexico market size and forecast, by end user
  • 7.3. Europe
    • 7.3.1. Key market trends and opportunities
    • 7.3.2. Market size and forecast, by therapeutics
    • 7.3.3. Market size and forecast, by application
    • 7.3.4. Market size and forecast, by end user
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. UK market size and forecast, by therapeutics
      • 7.3.5.2. UK market size and forecast, by application
      • 7.3.5.3. UK market size and forecast, by end user
      • 7.3.5.4. Germany market size and forecast, by therapeutics
      • 7.3.5.5. Germany market size and forecast, by application
      • 7.3.5.6. Germany market size and forecast, by end user
      • 7.3.5.7. France market size and forecast, by therapeutics
      • 7.3.5.8. France market size and forecast, by application
      • 7.3.5.9. France market size and forecast, by end user
      • 7.3.5.10. Italy market size and forecast, by therapeutics
      • 7.3.5.11. Italy market size and forecast, by application
      • 7.3.5.12. Italy market size and forecast, by end user
      • 7.3.5.13. Spain market size and forecast, by therapeutics
      • 7.3.5.14. Spain market size and forecast, by application
      • 7.3.5.15. Spain market size and forecast, by end user
      • 7.3.5.16. Rest of Europe market size and forecast, by therapeutics
      • 7.3.5.17. Rest of Europe market size and forecast, by application
      • 7.3.5.18. Rest of Europe market size and forecast, by end user
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends and opportunities
    • 7.4.2. Market size and forecast, by therapeutics
    • 7.4.3. Market size and forecast, by application
    • 7.4.4. Market size and forecast, by end user
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan market size and forecast, by therapeutics
      • 7.4.5.2. Japan market size and forecast, by application
      • 7.4.5.3. Japan market size and forecast, by end user
      • 7.4.5.4. China market size and forecast, by therapeutics
      • 7.4.5.5. China market size and forecast, by application
      • 7.4.5.6. China market size and forecast, by end user
      • 7.4.5.7. Australia market size and forecast, by therapeutics
      • 7.4.5.8. Australia market size and forecast, by application
      • 7.4.5.9. Australia market size and forecast, by end user
      • 7.4.5.10. India market size and forecast, by therapeutics
      • 7.4.5.11. India market size and forecast, by application
      • 7.4.5.12. India market size and forecast, by end user
      • 7.4.5.13. Rest of Asia-Pacific market size and forecast, by therapeutics
      • 7.4.5.14. Rest of Asia-Pacific market size and forecast, by application
      • 7.4.5.15. Rest of Asia-Pacific market size and forecast, by end user
  • 7.5. LAMEA
    • 7.5.1. Key market trends and opportunities
    • 7.5.2. Market size and forecast, by therapeutics
    • 7.5.3. Market size and forecast, by application
    • 7.5.4. Market size and forecast, by end user
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil market size and forecast, by therapeutics
      • 7.5.5.2. Brazil market size and forecast, by application
      • 7.5.5.3. Brazil market size and forecast, by end user
      • 7.5.5.4. Saudi Arabia market size and forecast, by therapeutics
      • 7.5.5.5. Saudi Arabia market size and forecast, by application
      • 7.5.5.6. Saudi Arabia market size and forecast, by end user
      • 7.5.5.7. South Africa market size and forecast, by therapeutics
      • 7.5.5.8. South Africa market size and forecast, by application
      • 7.5.5.9. South Africa market size and forecast, by end user
      • 7.5.5.10. Rest of LAMEA market size and forecast, by therapeutics
      • 7.5.5.11. Rest of LAMEA market size and forecast, by application
      • 7.5.5.12. Rest of LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

  • 8.1. AFFIMED N.V.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. CELGENE CORPORATION
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Product portfolio
    • 8.2.5. Business performance
    • 8.2.6. Key strategic moves and developments
  • 8.3. FATE THERAPEUTICS INC.
    • 8.3.1. Company overview
    • 8.3.2. Operating business segments
    • 8.3.3. Product portfolio
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. FORTRESS BIOTECH
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Product portfolio
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. GLYCOSTEM THERAPEUTICS BV
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Product portfolio
    • 8.5.5. Key strategic moves and developments
  • 8.6. INNATE PHARMA SA
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Product portfolio
    • 8.6.5. Business performance
    • 8.6.6. Key strategic moves and developments
  • 8.7. NANTKWEST INC
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. NKARTA THERAPEUTICS, INC.
    • 8.8.1. Company overview
    • 8.8.2. Operating business segments
    • 8.8.3. Product portfolio
    • 8.8.4. Key strategic moves and developments
  • 8.9. NKT THERAPEUTICS INC.
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Product portfolio
  • 8.10. ZIOPHARM ONCOLOGY INC.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance
    • 8.10.6. Key strategic moves and developments
Back to Top